UTORAL
KOREA UNITED PHARM
Identification
- Active ingredient (INN)
- FLUOROURACILE
- Internal code
- 05 G 059
- Country of Origin
- South Korea
- Pharmaceutical form
- Injectable Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/10 ampoules de 5 ml (250 mg/5ml) .b/10 flacon de 10 ml (500 mg/ml) .b/10 flacon de 20ml (1g/20ml)
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A pyrimidine analog that is an antineoplastic antimetabolite.
It interferes with
DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Indications
For the topical treatment of multiple actinic or solar keratoses.
In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.
Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
Pharmacodynamics
Fluorouracil is an antineoplastic anti-metabolite.
Anti-metabolites masquerade as purine or pyrimidine.
- which become the building blocks of DNA.
They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division.
Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative.
In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
Mechanism of Action
Incorporation into and destabilization RNA
Incorporation into and destabilization Thymidylate synthase Other/unknown.
Metabolism
The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and α-fluoro-ß-alanine) which are inactive.
Route of Elimination
Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.
The remaining percentage of the administered dose is metabolized, primarily in the liver.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.